U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H34N10O3
Molecular Weight 570.6455
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PKI-402

SMILES

CCN1N=NC2=C(N=C(N=C12)C3=CC=C(NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(C)CC5)C=C3)N6CCOCC6

InChI

InChIKey=ZAXFYGBKZSQBIV-UHFFFAOYSA-N
InChI=1S/C29H34N10O3/c1-3-39-27-24(34-35-39)26(37-16-18-42-19-17-37)32-25(33-27)20-4-8-22(9-5-20)30-29(41)31-23-10-6-21(7-11-23)28(40)38-14-12-36(2)13-15-38/h4-11H,3,12-19H2,1-2H3,(H2,30,31,41)

HIDE SMILES / InChI

Molecular Formula C29H34N10O3
Molecular Weight 570.6455
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19968288

PKI-402 is a reversible, ATP-competitive, and equipotent inhibitor of class I PI3Ks, including the E545K and H1047R PI3K-α mutants, and mTOR (IC50 versus PI3K-α = 2 nmol/L). Selectivity of PKI-402 was established in a screen against 236 diverse human kinases. PKI-402 caused in vitro growth inhibition of human tumor cell lines derived from a diverse set of human tumor tissues, including breast, brain (glioma), pancreas, and non–small cell lung cancer (NSCLC) tissues. In vivo, PKI-402 displayed antitumor activity (i.v. route) in breast [MDA-MB-361: Her2+ and PIK3- CA (E545K)], glioma (U87MG and PTEN), and NSCLC (A549; K-Ras and STK11) xenograft models. PKI-402 may be useful either as a single agent or in combination with cytostatic or cytotoxic (e.g., temozolomide) drugs in treatment of glioblastoma multiforme.

Approval Year

PubMed

PubMed

TitleDatePubMed
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
2010 Apr
Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
2010 Jan 28
Patents

Sample Use Guides

Mice: Single dose of PKI-402 (100 mg/kg) suppresses Akt phosphorylation (at T308) and induces cleaved PARP in MDA-MB-361 tumors. PKI-402 significantly inhibits the growth of A549 tumors in nude mice at 25 mg/kg and 50 mg/kg. PKI-402 at 100 mg/kg (daily for 5 days, one round) causes significant reduction in tumor growth of U87MG.
Route of Administration: Intravenous
Less than 10% of MDAMB-361 cells exposed to PKI-402 at 0.3 uM (or higher) for 24 hours remain viable.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:45:16 GMT 2023
Edited
by admin
on Sat Dec 16 09:45:16 GMT 2023
Record UNII
A5XSH56P2N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PKI-402
Code English
UREA, N-(4-(3-ETHYL-7-(4-MORPHOLINYL)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-5-YL)PHENYL)-N'-(4-((4-METHYL-1-PIPERAZINYL)CARBONYL)PHENYL)-
Systematic Name English
PKI402
Code English
N-(4-(3-ETHYL-7-(4-MORPHOLINYL)-3H-1,2,3-TRIAZOLO(4,5-D)PYRIMIDIN-5-YL)PHENYL)-N'-(4-((4-METHYL-1-PIPERAZINYL)CARBONYL)PHENYL)UREA
Systematic Name English
1-(4-(3-ETHYL-7-(MORPHOLIN-4-YL)-3H-(1,2,3)TRIAZOLO(4,5-D)PYRIMIDIN-5-YL)PHENYL)-3-(4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)PHENYL)UREA
Systematic Name English
Code System Code Type Description
PUBCHEM
44187953
Created by admin on Sat Dec 16 09:45:16 GMT 2023 , Edited by admin on Sat Dec 16 09:45:16 GMT 2023
PRIMARY
EPA CompTox
DTXSID30657809
Created by admin on Sat Dec 16 09:45:16 GMT 2023 , Edited by admin on Sat Dec 16 09:45:16 GMT 2023
PRIMARY
FDA UNII
A5XSH56P2N
Created by admin on Sat Dec 16 09:45:16 GMT 2023 , Edited by admin on Sat Dec 16 09:45:16 GMT 2023
PRIMARY
CAS
1173204-81-3
Created by admin on Sat Dec 16 09:45:16 GMT 2023 , Edited by admin on Sat Dec 16 09:45:16 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY